# BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT

> **NCT02670252** · PHASE3 · COMPLETED · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 550 (actual)

## Conditions studied

- Allogeneic Hematopoietic Stem Cell Transplantation
- Busulfan
- Total Body Irradiation
- Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** Busulfan (BU)
- **DRUG:** Cyclophosphamide (CY)
- **RADIATION:** Total Body Irradiation (TBI)

## Key facts

- **NCT ID:** NCT02670252
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2020-02
- **Final completion:** 2022-02
- **Target enrollment:** 550 (ACTUAL)
- **Last updated:** 2022-04-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02670252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02670252, "BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02670252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*